About Levocetirizine Dihydrochloride API
Therapeutic CategoryRespiratory
CAS Number
130018-87-0
API Technology
Synthetic
Dose Form
Solution/Tablet
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, Brazil DMF, EUDMF, Korea DMF, CEP Submitted
Mechanism of Action
Levocetirizine, the active enantiomer of cetirizine, is an antihistamine; its principal effects are mediated via selective inhibition of H1 receptors. The antihistaminic activity of levocetirizine has been documented in a variety of animal and human models. In vitro binding studies revealed that levocetirizine has an affinity for the human H1-receptor 2-fold higher than that of cetirizine (Ki = 3 nmol/L vs. 6 nmol/L, respectively). The clinical relevance of this finding is unknown.
Indication
XYZAL is a histamine H1-receptor antagonist indicated for:
- The relief of symptoms associated with perennial allergic rhinitis
- The treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria
Related APIs
Cetirizine Dihydrochloride
Respiratory
Desloratadine
Respiratory
Levocetirizine Dihydrochloride
Respiratory
Montelukast Sodium
Respiratory
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
FAQs
Treats symptoms of allergic rhinitis and chronic idiopathic urticaria
-
Available as oral tablets (5 mg) and oral solution (2.5 mg/5 mL)
-
Relieves allergy symptoms like runny nose, sneezing, and itching Reduces hives and associated itching
-
Store at 20°C to 25°C (68°F to 77°F), in a cool, dry place, away from moisture and heat
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.